76.85 USD
-0.39 (-0.5%)
76.85 USD
0 (0%)
PTCT gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. PTCT has only an average score on both its financial health and profitability. PTCT is growing strongly while it is still valued neutral. This is a good combination! With these ratings, PTCT could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
In the past year PTCT was profitable.
PTCT had a positive operating cash flow in the past year.
In the past 5 years PTCT always reported negative net income.
In the past 5 years PTCT always reported negative operating cash flow.
1.2 Ratios
PTCT has a better Return On Assets (28.43%) than 97.92% of its industry peers.
With an excellent Return On Invested Capital value of 41.48%, PTCT belongs to the best of the industry, outperforming 99.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.43% | ||
| ROE | N/A | ||
| ROIC | 41.48% |
ROA(3y)-29.05%
ROA(5y)-26.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PTCT has a Profit Margin of 42.25%. This is amongst the best in the industry. PTCT outperforms 97.55% of its industry peers.
PTCT has a better Operating Margin (52.45%) than 99.62% of its industry peers.
Looking at the Gross Margin, with a value of 96.83%, PTCT belongs to the top of the industry, outperforming 96.79% of the companies in the same industry.
In the last couple of years the Gross Margin of PTCT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 52.45% | ||
| PM (TTM) | 42.25% | ||
| GM | 96.83% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y-0.66%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), PTCT is creating value.
Compared to 1 year ago, PTCT has more shares outstanding
PTCT has more shares outstanding than it did 5 years ago.
The debt/assets ratio for PTCT is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.18 indicates that PTCT is not a great score, but indicates only limited risk for bankruptcy at the moment.
PTCT's Altman-Z score of 2.18 is fine compared to the rest of the industry. PTCT outperforms 66.79% of its industry peers.
PTCT has a debt to FCF ratio of 3.38. This is a good value and a sign of high solvency as PTCT would need 3.38 years to pay back of all of its debts.
PTCT has a better Debt to FCF ratio (3.38) than 92.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.38 | ||
| Altman-Z | 2.18 |
ROIC/WACC5.69
WACC7.29%
2.3 Liquidity
PTCT has a Current Ratio of 2.32. This indicates that PTCT is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of PTCT (2.32) is worse than 72.08% of its industry peers.
PTCT has a Quick Ratio of 2.26. This indicates that PTCT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.26, PTCT is doing worse than 70.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.32 | ||
| Quick Ratio | 2.26 |
3. Growth
3.1 Past
PTCT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 277.07%, which is quite impressive.
Looking at the last year, PTCT shows a very strong growth in Revenue. The Revenue has grown by 97.54%.
Measured over the past years, PTCT shows a very strong growth in Revenue. The Revenue has been growing by 21.32% on average per year.
EPS 1Y (TTM)277.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.39%
Revenue 1Y (TTM)97.54%
Revenue growth 3Y14.42%
Revenue growth 5Y21.32%
Sales Q2Q%7.23%
3.2 Future
The Earnings Per Share is expected to grow by 25.49% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 17.10% on average over the next years. This is quite good.
EPS Next Y259.3%
EPS Next 2Y35.88%
EPS Next 3Y29.67%
EPS Next 5Y25.49%
Revenue Next Year121.54%
Revenue Next 2Y9.72%
Revenue Next 3Y13.49%
Revenue Next 5Y17.1%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 10.59, which indicates a very decent valuation of PTCT.
Based on the Price/Earnings ratio, PTCT is valued cheaper than 97.74% of the companies in the same industry.
PTCT's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.00.
The Forward Price/Earnings Ratio is negative for PTCT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.59 | ||
| Fwd PE | N/A |
4.2 Price Multiples
98.49% of the companies in the same industry are more expensive than PTCT, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, PTCT is valued cheaply inside the industry as 99.25% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.75 | ||
| EV/EBITDA | 6.06 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PTCT's earnings are expected to grow with 29.67% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y35.88%
EPS Next 3Y29.67%
5. Dividend
5.1 Amount
PTCT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
76.85
-0.39 (-0.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners105.27%
Inst Owner Change0%
Ins Owners0.73%
Ins Owner Change5.18%
Market Cap6.17B
Revenue(TTM)1.78B
Net Income(TTM)751.72M
Analysts79.09
Price Target83.37 (8.48%)
Short Float %14.62%
Short Ratio7.2
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)68.83%
Min EPS beat(2)23.33%
Max EPS beat(2)114.33%
EPS beat(4)3
Avg EPS beat(4)1164.83%
Min EPS beat(4)-221.32%
Max EPS beat(4)4742.99%
EPS beat(8)5
Avg EPS beat(8)562.98%
EPS beat(12)5
Avg EPS beat(12)357.38%
EPS beat(16)5
Avg EPS beat(16)260.9%
Revenue beat(2)2
Avg Revenue beat(2)7.12%
Min Revenue beat(2)2.58%
Max Revenue beat(2)11.67%
Revenue beat(4)3
Avg Revenue beat(4)147.37%
Min Revenue beat(4)-10.09%
Max Revenue beat(4)585.33%
Revenue beat(8)5
Avg Revenue beat(8)76.88%
Revenue beat(12)7
Avg Revenue beat(12)50.21%
Revenue beat(16)10
Avg Revenue beat(16)38.94%
PT rev (1m)3.62%
PT rev (3m)22.72%
EPS NQ rev (1m)0.73%
EPS NQ rev (3m)40.88%
EPS NY rev (1m)1.05%
EPS NY rev (3m)25.83%
Revenue NQ rev (1m)0.17%
Revenue NQ rev (3m)17.74%
Revenue NY rev (1m)-0.43%
Revenue NY rev (3m)3.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.59 | ||
| Fwd PE | N/A | ||
| P/S | 3.47 | ||
| P/FCF | 8.75 | ||
| P/OCF | 8.62 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.06 |
EPS(TTM)7.26
EY9.45%
EPS(NY)-0.92
Fwd EYN/A
FCF(TTM)8.78
FCFY11.43%
OCF(TTM)8.91
OCFY11.6%
SpS22.16
BVpS-1.94
TBVpS-7.9
PEG (NY)0.04
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.43% | ||
| ROE | N/A | ||
| ROCE | 52.5% | ||
| ROIC | 41.48% | ||
| ROICexc | 822.48% | ||
| ROICexgc | N/A | ||
| OM | 52.45% | ||
| PM (TTM) | 42.25% | ||
| GM | 96.83% | ||
| FCFM | 39.64% |
ROA(3y)-29.05%
ROA(5y)-26.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y-0.66%
F-Score7
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.38 | ||
| Debt/EBITDA | 1.9 | ||
| Cap/Depr | 31.38% | ||
| Cap/Sales | 0.58% | ||
| Interest Coverage | 163.67 | ||
| Cash Conversion | 74.07% | ||
| Profit Quality | 93.81% | ||
| Current Ratio | 2.32 | ||
| Quick Ratio | 2.26 | ||
| Altman-Z | 2.18 |
F-Score7
WACC7.29%
ROIC/WACC5.69
Cap/Depr(3y)15.16%
Cap/Depr(5y)26.1%
Cap/Sales(3y)2.81%
Cap/Sales(5y)3.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)277.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.39%
EPS Next Y259.3%
EPS Next 2Y35.88%
EPS Next 3Y29.67%
EPS Next 5Y25.49%
Revenue 1Y (TTM)97.54%
Revenue growth 3Y14.42%
Revenue growth 5Y21.32%
Sales Q2Q%7.23%
Revenue Next Year121.54%
Revenue Next 2Y9.72%
Revenue Next 3Y13.49%
Revenue Next 5Y17.1%
EBIT growth 1Y813.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year785.86%
EBIT Next 3Y63.36%
EBIT Next 5YN/A
FCF growth 1Y375.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y419.28%
OCF growth 3YN/A
OCF growth 5YN/A
PTC THERAPEUTICS INC / PTCT FAQ
What is the ChartMill fundamental rating of PTC THERAPEUTICS INC (PTCT) stock?
ChartMill assigns a fundamental rating of 5 / 10 to PTCT.
What is the valuation status for PTCT stock?
ChartMill assigns a valuation rating of 6 / 10 to PTC THERAPEUTICS INC (PTCT). This can be considered as Fairly Valued.
Can you provide the profitability details for PTC THERAPEUTICS INC?
PTC THERAPEUTICS INC (PTCT) has a profitability rating of 5 / 10.
Can you provide the PE and PB ratios for PTCT stock?
The Price/Earnings (PE) ratio for PTC THERAPEUTICS INC (PTCT) is 10.59 and the Price/Book (PB) ratio is -39.61.